Maria Tampaki

Dr. Maria Tampaki

School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Attikí, Greece
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2021 in Hepatology
Verified
Journal Article
Closed access
PDF file
MPMargarita Papatheodoridi
Margarita Papatheodoridi
Maria TampakiMaria Tampaki
Maria Tampaki
ALAnna S. Lok
Anna S. Lok
George PapatheodoridisGeorge Papatheodoridis
George Papatheodoridis

10 December 2024 in Metabolism
Verified
Journal Article
Closed access
Maria TampakiMaria Tampaki
Maria Tampaki
ETEmmanouil Tsochatzis
Emmanouil Tsochatzis
VLVasileios Lekakis
Vasileios Lekakis
ECEvangelos Cholongitas
Evangelos Cholongitas

15 January 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Maria TampakiMaria Tampaki
Maria Tampaki
EIEvangelos Ionas
Evangelos Ionas
EHEmilia Hadziyannis
Emilia Hadziyannis
MDMelanie Deutsch
Melanie Deutsch
KMKATERINA MALAGARI
KATERINA MALAGARI
John KoskinasJohn Koskinas
John Koskinas
Considering the increasing importance of immune checkpoints in tumor immunity we investigated the clinical relevance of serum T-cell immunoglobulin and mucin domain-3 (TIM-3) in patients with hepatocellular carcinoma (HCC). Serum TIM-3 levels were measured and their association with HCC stage and the detection of serum programmed death ligand-1 (PD-L1) were assessed. In patients submitted to transarterial chemoembolization (TACE), pre- and 1-week post-treatment TIM-3 levels were also evaluated. We studied 53 HCC patients with BCLC stages: 0 (5.7%), A (34%), B (32.1%), C (22.6%), and D (5.7%). The patients with advanced HCC (BCLC C) had significantly higher TIM-3 levels than patients with BCLC A (p = 0.009) and BCLC B (p = 0.019). TIM-3 levels were not associated with HCC etiology (p = 0.183). PD-L1 detection (9/53 patients) correlated with TIM-3 levels (univariate analysis, p = 0.047). In 33 patients who underwent TACE, post-treatment TIM-3 levels (231 pg/mL, 132–452) were significantly higher than pre-TACE levels (176 pg/mL, 110–379), (p = 0.036). Complete responders had higher post-TACE TIM-3 levels (534 pg/mL, 370–677) than partial responders (222 pg/mL, 131–368), (p = 0.028). Collectively, TIM-3 may have a role in anti-tumor immunity following TACE, setting a basis for combining immunotherapy and chemoembolization.

25 April 2017 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
ESEmmanouil Sinakos
Emmanouil Sinakos
DKDimitrios Kountouras
Dimitrios Kountouras
JKJohn Koskinas
John Koskinas
KZKalliopi Zachou
Kalliopi Zachou
SKStylianos Karatapanis
Stylianos Karatapanis
George PapatheodoridisGeorge Papatheodoridis
George Papatheodoridis

6 March 2013 in Clinical and Vaccine Immunology
Verified
Journal Article
Closed access
PDF file
MMMartha Minopetrou
Martha Minopetrou
EHEmilia Hadziyannis
Emilia Hadziyannis
MDMelanie Deutsch
Melanie Deutsch
Maria TampakiMaria Tampaki
Maria Tampaki
AGAsimina Georgiadou
Asimina Georgiadou
JKJohn Koskinas
John Koskinas
Cryoglobulin characteristics in chronic hepatitis C (CHC) might be of importance for knowing more about the pathogenesis and treatment of the disease. We aimed to investigate the relationship between cryoglobulin types and their specificity against hepatitis C virus (HCV) antigenic epitopes in CHC patients. We analyzed samples from 43 patients with HCV-associated cryoglobulinemia, of whom 4 had concomitant lymphoma. Cryoglobulins were measured, purified, typed by immunofixation electrophoresis, and tested for IgG and IgM anti-HCV antibodies by immunoblot analysis and an enzyme-linked immunosorbent assay (ELISA). Clinical and other laboratory data were recorded. The median cryocrit level of the tested samples was 6%. Type I cryoglobulins were detected in 9.3% (4/43) of the cryoprecipitates, and type II cryoglobulins were detected in 48.8% (21/43) of the cryoprecipitates. IgM monoclonal protein, mainly IgM(κ), was found in 92% (23/25) of type I and II cryoprecipitates. Type III cryoglobulins were identified in 41.9% (18/43) of the patients and were associated with high blood serum IgG levels. In 81.3% (13/16) of type II and 92.3% (12/13) of type III cryoglobulins, there was IgG reactivity against the viral core region. Ninety-two percent and 32% of IgG anti-HCV core-positive cryoprecipitates had additional specificities against the NS3 and NS4 regions, respectively. Also, IgM anti-HCV antibodies were detected in 31% of the cryoprecipitates. In conclusion, all types of cryoglobulins were found in patients with HCV-associated cryoglobulinemia, with type II being the most frequently identified. Type III cryoglobulins were common and were associated with high serum IgG levels. HCV-related cryoglobulins demonstrated IgM, and particularly IgG, anti-HCV specificities, mainly against the core and NS3 epitopes.

1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
Maria TampakiMaria Tampaki
Maria Tampaki
JKJohn Koskinas
John Koskinas
The association of chronic hepatitis C with immune related syndromes has been frequently reported. There is a great range of clinical manifestations affecting various systems and organs such as the skin, the kidneys, the central and peripheral nervous system, the musculoskeletal system and the endocrine glands. Despite the high prevalence of immune related syndromes in patients with chronic hepatitis C, the exact pathogenesis is not always clear. They have been often associated with mixed cryoglobulinemia, a common finding in chronic hepatitis C, cross reaction with viral antigens, or the direct effect of virus on the affected tissues. The aim of this review is to analyze the reported hepatitis C virus immune mediated syndromes, their prevalence and clinical manifestations and to discuss the most supported theories regarding their pathogenesis.